Benitec Biopharma Inc. (NASDAQ: BNTC) stock gains by 2.67% in the current market trading session. Benitec Biopharma based in Hayward, California, is a development-stage biotechnology firm that deals with the advancement of innovative genetic therapeutics.
BNTC stock Significant Development
The essential aspects of the BB-301 Phase 1b/2a clinical trial design were discussed by Benitec Biopharma Inc. The clinical trial is set to begin in 2022.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
BB-301 is indeed a unique investigational gene therapy that is being developed for the cure of Oculopharyngeal Muscular Dystrophy patients (OPMD). OPMD is a deadly, severe genetic condition that affects about 15,000 people in the United States, Canada, Western Europe, and Israel. A mutation in the gene encoding poly(A) binding protein nuclear 1 causes OPMD (PABPN1). Individuals with OPMD lose their capacity to swallow liquids and solids, and the disorder’s natural history includes chronic starvation, aspiration, and deadly aspiration pneumonia episodes. There are currently not authorized therapeutic medicines for the treatment of OPMD. Furthermore, there are no surgical procedures that can affect the long-term natural history of OPMD.
The preliminary interim data points from the BB-301 Pilot Dosing Study were gathered from completed studies of pharyngeal muscle tissues taken from 6 Beagle dog subjects and delivered in February 2021 through press release and conference. The data-points collected from 16 Beagle dog subjects are used in the updated analyses of the BB-301 Pilot Dosing Study participants. The canine participants administered in the 24-subject BB-301 Pilot Dosing Study are still being analyzed.
Objectives of the BB-301 Phase 1b/2a Study
- The essential physiological mechanisms enabling the proper completion of the pharyngeal phase of swallowing are accurately and reproducibly characterized by Benitec.
- In this context, the clinical study’s primary analytical techniques and methods will concentrate on operational measures of swallowing efficiency in OPMD patients during the pharyngeal phase of swallowing.